There are 2789 resources available
1315P - Impact of high fasting plasma glucose in the clinical outcome of patients with advanced NSCLC with PD-L1 ≥ 50% treated with frontline pembrolizumab
Presenter: Sandra Llop Serna
Session: ePoster Display
1317P - Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy
Presenter: Nino Balanchivadze
Session: ePoster Display
1319P - Impact of bone radiotherapy on immune checkpoint inhibitors efficacy in patients with metastatic non-small cell lung cancer: A single-institution experience
Presenter: guido natoli
Session: ePoster Display
1320TiP - The efficacy and safety of stereotactic body radiation therapy (SBRT) plus toripalimab with or without bevacizumab as second-line treatment for advanced non-small cell lung cancer (NSCLC): A prospective, multicenter, open-label, phase II study
Presenter: Jianguo Sun
Session: ePoster Display
1321P - Real-world treatments and clinical outcomes in advanced NSCLC without actionable mutations after introduction of immunotherapy (IO) in Japan
Presenter: Hiroshi Nokihara
Session: ePoster Display
1322P - Development and external validation of a novel four-gene-pair signature for predicting clinical response to anti-PD-1 immunotherapy of non-small cell lung cancer
Presenter: Chengming Liu
Session: ePoster Display
1323P - Immunotherapy for PDL1-high (TPS≥50%) metastatic NSCLC: Results in real-world oncology practice
Presenter: Drazena Srdic
Session: ePoster Display
1324P - Clinical and laboratory features: How they influence immunotherapy response in non-small cell lung cancer
Presenter: Ricardo Gomes
Session: ePoster Display